Deutsche Bank just gave Idenix (Nasdaq: IDIX ) a big buy recommendation, projecting a stock price of $7 per share, which is more than 55% higher than what the stock closed at yesterday, and the stock climbed 15% as a result. Its drug IDX-184 is still in development and on clinical hold because of its similarities with a drug from Bristol-Myers Squibb (NYSE: BMY ) that had catastrophic results. But it's aimed at the hottest area in health care right now -- the treatment of hepatitis-C -- and Deutsche Bank thinks it is significantly different from Bristol's drug. Many wonder, however, if it isn't too late for a small company to enter this space, as drug cocktails demonstrating miraculous cure rates are already further along in development from both Abbott Labs (NYSE: ABT ) and Gilead (Nasdaq: GILD ) .
See more in the following video.
With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.